

Sareum Holdings plc
("Sareum" or the "Company")

Management Changes

Cambridge, UK, 10 July 2024- Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces certain management team changes.

Dr. Tim Mitchell, co-founder and Chief Executive Officer (CEO), will, after twenty years with the Company, transition to the part-time role of Chief Operating Officer (COO). Dr. Mitchell will continue to serve on Sareum's Board of Directors (the "Board").

Dr. Stephen Parker, currently Non-Executive Chairman, will assume the position of Executive Chairman on the Board. The Board currently intends to seek to appoint a new CEO, at the appropriate time, as the Company and its future strategy develops.

Additionally, Mr. Clive Birch has been appointed as Senior Independent Director.

Dr. Stephen Parker, Executive Chairman at Sareum, commented: *"I'm really excited to be stepping into the position of Executive Chairman at Sareum at this critical time in the Company's history. Tim's decision to transition to the part-time role of COO comes at a time when we have achieved an important milestone of positive data from the Phase 1 trial of our lead product, SDC-1801. I would like to acknowledge the immense contribution Tim has made since founding the company twenty years ago. I wish him well as he takes up his new role at Sareum and I'm very pleased that we will continue to benefit from his expertise and experience."*

Dr. Tim Mitchell, Chief Operating Officer of Sareum added *"After many years as CEO, I am looking forward to transitioning into the role of Chief Operating Officer. I will continue to support Sareum's mission and work closely with Stephen and the Board as we advance the development of our pipeline. The positive data from the Phase 1 clinical trial of SDC-1801 highlights the potential of our lead product and sets a solid foundation for the future."*

- END -

For Further Information:

Sareum Holdings plc
Stephen Parker, Executive Chairman

01223 497700
ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman

020 7409 3494

Hybridan LLP (Corporate Broker)
Claire Noyce

020 3764 2341

ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Kumail Waljee

0203 709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGZGGNVLZGDZM